Dyne Therapeutics, Inc. — Q3 2020 Form 10-Q
Reporting period: Three and nine months ended September 30, 2020. Dyne is a preclinical biotechnology company developing muscle-targeted oligonucleotide therapeutics using its FORCE platform. Its DM1, DMD and FSHD programs were all preclinical; the company had no products for sale and no revenue.
Financial performance and position
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $9.7 million | $3.0 million | $23.1 million | $6.8 million |
| General and administrative expense | $3.8 million | $0.6 million | $6.9 million | $1.6 million |
| Total operating expenses | $13.5 million | $3.6 million | $30.0 million | $8.4 million |
| Net loss | $13.9 million | $5.9 million | $30.8 million | $9.5 million |
| Net loss per share, basic and diluted | $2.01 | $2.36 | $7.51 | $3.94 |
As of September 30, 2020, cash and cash equivalents were $379.6 million, total assets $381.5 million, current liabilities $4.7 million and total liabilities $14.6 million, including $9.9 million of long-term debt net of discount. Stockholders’ equity was $366.8 million; accumulated deficit was $50.5 million. No meaningful operating margins are applicable because the company had no revenue.
For the first nine months, operating cash use was $26.5 million, investing cash use $0.4 million and financing cash inflow $391.9 million, producing a $365.0 million increase in cash. Financing included $246.4 million net IPO proceeds, $134.9 million net preferred-stock proceeds and $10.0 million of debt proceeds. The company repaid the $10.0 million loan principal and approximately $17,000 accrued interest in October 2020; it had also paid a $0.5 million loan success fee after the IPO.
Changes versus the prior comparable period
- Operating expenses and net loss increased substantially year over year as research activity, external manufacturing and research spending, and headcount expanded. Nine-month R&D expense rose by $16.3 million, driven chiefly by external manufacturing and research costs.
- G&A growth reflected higher headcount, stock-based compensation, professional fees and preparation for public-company obligations. Q3 2020 included $2.2 million of stock-based compensation across R&D and G&A, versus $7,000 in Q3 2019.
- Net loss per share was lower in Q3 2020 than Q3 2019 despite the larger net loss, in part because the weighted-average share count increased. For the nine-month comparison, loss per share increased.
- The September 2020 IPO raised $246.4 million net. Preferred stock issued in July and August converted into common stock upon the IPO; the company ended the period with no preferred stock outstanding.
Outlook, commentary and risks
- Management expected cash to fund operating expenses and capital requirements into the second half of 2023, and to support IND submissions for DM1, DMD and FSHD and proof-of-concept readouts in DM1 and DMD. These estimates depend on assumptions that could prove wrong. The financial-statement note separately states cash was expected to cover at least 12 months from issuance of the statements.
- Management expected to submit IND applications for the three programs between Q4 2021 and Q4 2022. These were forward-looking targets, not achieved milestones. The filing emphasizes that the programs were preclinical and no product candidates had yet been identified for IND-enabling studies or clinical development.
- Operating losses and expenses were expected to increase as research, preclinical development, manufacturing preparations and public-company costs expanded. The company anticipated needing substantial additional funding; future equity financing could dilute shareholders, while debt, collaborations or licenses could restrict operations or require relinquishing rights.
- The 2019 auditor’s report had included a going-concern explanatory paragraph. Following the IPO, management stated its cash runway expectation described above, while warning that spending or development changes could shorten it.
- COVID-19 had not caused material business disruptions, including with vendors, as of the filing’s discussion; however, the company described potential effects on research capacity, supplies, preclinical work, future trials, regulatory activity and financing markets. The risk-factor discussion also notes reduced research-scale production and execution capacity at the company and its vendors.
- Other prominent risks include high preclinical and clinical failure risk, reliance on third-party and single-source suppliers, manufacturing and regulatory hurdles, uncertain intellectual-property protection, competition, and the difficulty of recruiting patients for rare-disease trials. No material legal proceedings were reported.
Important facts for investors to verify
- Whether program progress supports the stated IND and proof-of-concept timelines, and whether any candidates have advanced to IND-enabling work.
- Whether cash use remains consistent with the projected runway into the second half of 2023, including the effect of the October debt repayment and planned development spending.
- Whether COVID-19 or supplier/manufacturing constraints have materially affected research execution, timelines or costs since the reporting date.
- Potential dilution and share supply: the IPO, substantial outstanding equity awards and shares subject to lock-ups or registration rights.
- The nine-month G&A figure is shown as $6.945 million in the statements and $6.946 million in the MD&A table; confirm the intended rounded amount.